ABSTRACT Many factors can interfere with glycemic control in patients with type 2 diabetes mellitus and this patient group has an increased risk of experiencing drug-related negative outcomes (DNO). T

NIAID Data Ecosystem20

Trends in severe cutaneous adverse drug reactions before, during, and after the COVID-19 pandemic: a retrospective multicenter of 794 cases

药物不良反应监测

皮肤不良反应(SCARs)

Supplemental figure: Suspected culprit drug (single or multiple) in association with SCARs among the three phases of COVID-19.

NIAID Data Ecosystem10

Rapid Ventricular Tachycardias Associated with Cilostazol Use

药物不良反应监测

心血管事件风险

A 92-year-old woman with normal systolic function had recently begun using the newly approved phosphodiesterase III inhibitor cilostazol when she was admitted with lower-extremity pain. Cilostazol is

PubMed Central30

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

慢性肾脏病用药安全

药物不良反应监测

Data on hyperkalemia frequency among chronic kidney disease (CKD) patients receiving renin-angiotensin aldosterone system inhibitors (RAASis) and its impact on subsequent RAASi treatment are limited.

Figshare2019-03-07 更新10

Incidence for proteinuria with VEGFR-TKIs according to drugs and tumor types.

资源简介：

相关数据集